“The benefit-risk profile favored Pola-R-CHP vs R-CHOP in elderly patients with previously untreated DLBCL. Results were consistent with those of the overall POLARIX population and suggest that ...

Researchers identified nearly 50,000 patients diagnosed with DLBCL over a 15-year period to measure the impact of SES on 5-year overall survival (OS). Patients living in low SES regions had ...

These investigators assessed the potential benefit of a high-risk signature to evaluate the molecular drivers of primary treatment resistance in patients with DLBCL. A recent study published in ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within ...

ADC Therapeutics (NYSE:ADCT) is continuing to make strides with the advancement of its drug ZYNLONTA [Loncastuximab Tesirine-lpyl] for the treatment of patients with DLBCL. Specifically ...

An initial efficacy analysis was conducted on all 18 evaluable 2L+ DLBCL patients who received dose levels of ... of Grade 1 or 2 according to ASTCT grading was observed in 34.5% of patients and ...

Overexpression of MYC and BCL2 in DLBCL is linked to increased CCL2 and CCR2, promoting M2 macrophage polarization and aggressiveness. Elevated CCL2 and CCR2 expression correlates with poor ...

One such lymphoma is DLBCL (diffuse large B-cell lymphoma), a prevalent form of NHL (non-Hodgkin lymphoma), arises when B-cells, the body's infection-fighting white blood cells, undergo abnormal ...

Roche’s up-and-coming Columvi has demonstrated it could save lives when used as a second-line therapy in diffuse large B-cell lymphoma (DLBCL). But the Swiss pharma still finds itself fielding ...

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states. The methods of subtyping diffuse large B-cell lymphoma (DLBCL) have changed ...